| Followers | 10 |
| Posts | 1467 |
| Boards Moderated | 0 |
| Alias Born | 07/16/2006 |
Wednesday, September 18, 2013 6:45:11 PM
In reply to a buy at a discount from an insider let us look at some facts as I understand the rules.
1. NNVC is not yet in a quiet period. That means DR B. can buy or sell as he pleases. He chose to buy. All the knowledge that he has is the same as what has been released. HE CHOSE TO BUY!!!
2. When NNVC starts the tox testing this will put the co. into a quiet period. The insiders may not buy or sell during this time.
This give US an equal or better footing on preventing a loss or making a gain.
3. IF Dr. B decided to sell he would need to issue an SEC form 4, I think, telling us this happened. So, we know that he hasn't taken a profit on his buy.
4. What exactly is meant by starting TOX testing? Begin the paper work? Buy insurance? Make the product? Test the product to see if it meet the quality standard for human injections? Select the facility? Have their IRB ok NNVCs plans to begin testing in their hospital? Or, just the first injection? This is quite a process and we don't know which part is the START point.
For me just announcing that it will happen is the START!
With the increase in the stock price we must be somewhere on the road. I believe that one morning we will se a PR saying that yesterday the first cohort was started with the injection. I don't believe that they will announce each injection, but wait until the cohort has all been injected. How many days after the first injection until the second? Only time will tell. How long until all have been injected and the results published? About 3 months IMHO
1. NNVC is not yet in a quiet period. That means DR B. can buy or sell as he pleases. He chose to buy. All the knowledge that he has is the same as what has been released. HE CHOSE TO BUY!!!
2. When NNVC starts the tox testing this will put the co. into a quiet period. The insiders may not buy or sell during this time.
This give US an equal or better footing on preventing a loss or making a gain.
3. IF Dr. B decided to sell he would need to issue an SEC form 4, I think, telling us this happened. So, we know that he hasn't taken a profit on his buy.
4. What exactly is meant by starting TOX testing? Begin the paper work? Buy insurance? Make the product? Test the product to see if it meet the quality standard for human injections? Select the facility? Have their IRB ok NNVCs plans to begin testing in their hospital? Or, just the first injection? This is quite a process and we don't know which part is the START point.
For me just announcing that it will happen is the START!
With the increase in the stock price we must be somewhere on the road. I believe that one morning we will se a PR saying that yesterday the first cohort was started with the injection. I don't believe that they will announce each injection, but wait until the cohort has all been injected. How many days after the first injection until the second? Only time will tell. How long until all have been injected and the results published? About 3 months IMHO
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
